Epigenetic nutraceutical diets in Alzheimer’s disease

Journal of Nutrition, Health and Aging

Volumn 18, Issue 9, 2014, Pages 800-805

  Davinelli, S ^a,b   Calabrese, V ^b,c   Zella, D ^d   Scapagnini, Giovanni ^a,b  

^a UNIVERSITY OF MOLISE   (Italy)

^b Inter University Consortium SannioTech   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer; diet; Epigenetic; nutraceutical

Indexed keywords

HISTONE; MICRORNA; NUTRACEUTICAL;

ALZHEIMER DISEASE; ARTICLE; DIET; DNA METHYLATION; EPIGENETICS; FOOD COMPOSITION; HISTONE MODIFICATION; HUMAN; NERVE DEGENERATION; NUTRITION; PATHOPHYSIOLOGY; REGULATORY MECHANISM;

EID: 84919727487     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-014-0552-y     Document Type: Article

References (76)

1. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004;430(7000):631–639.
2. Bihaqi SW, Schumacher A, Maloney B, et al. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 2012;9(5):574–588.
3. Adwan L, Zawia NH. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer’s disease. Pharmacol Ther 2013;139(l):41–50.
4. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 2012;13(2):97–109.
5. Choi SW, Friso S. Epigenetics: A New Bridge between Nutrition and Health. Adv Nutr 2010;1(1):8–16.
6. Jiménez-Chillarón JC, Díaz R, Martínez D, et al. The role of nutrition on epigenetic modifications and their implications on health. Biochimie. 2012;94(11):2242–2263.
7. Ramesh BN, Rao TS, Prakasam A, et al. Neuronutrition and Alzheimer’s disease. J Alzheimers Dis 2010;19(4):1123–1139.
8. Davinelli S, Sapere N, Zella D, et al. Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid Med Cell Longev 2012:386527.
9. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 2008;9(7):568–578.
10. Malireddy S, Kotha SR, Secor JD, et al. Phytochemical antioxidants modulate mammalian cellular epigenome: implications in health and disease. Antioxid Redox Signal 2012;17(2):327–339.
11. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of Alzheimer’s disease. Mech Ageing Dev 2013;134(10):486–495.
12. Mastroeni D, Grover A, Delvaux E, et al. Epigenetic mechanisms in Alzheimer’s disease. Neurobiol Aging 2011;32(7):1161–1180.
13. Tchantchou F, Graves M, Ortiz D, et al. S-adenosyl methionine: A connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer’s disease. J Nutr Health Aging 2006;10(6):541–544.
14. Guo JU, Ma DK, Mo H, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 2011;14(10):1345–1351.
15. Pogribny IP, Beland FA. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 2009;66(14):2249–2261.
16. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer’s disease patient. J Mol Neurosci 1995;6(2):141–146.
17. Mulder C, Schoonenboom NS, Jansen EE, et al. The transmethylation cycle in the brain of Alzheimer patients. Neurosci Lett 2005;386(2):69–71.
18. Bakulski KM, Dolinoy DC, Sartor MA, et al. Genome-wide DNA methylation differences between late-onset Alzheimer’s disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 2012;29(3):571–588.
19. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One 2008;3(7):e2698.
20. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261(5123):921–923.
21. Coppieters N, Dieriks BV, Lill C, et al. Global changes in DNA methylation and hydroxymethylation in Alzheimer’s disease human brain. Neurobiol Aging pii:S 0197–2013;4580(13)00615-5.
22. Mill J. Toward an integrated genetic and epigenetic approach to Alzheimer’s disease. Neurobiol Aging 2011;32(7): 1188–1191.
23. Coppedè F. One-carbon metabolism and Alzheimer’s disease: focus on epigenetics. Curr Genomics 2010;ll(4):246–260.
24. Fuso A, Seminara L, Cavallaro RA, et al. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28(l):195–204.
25. Bacalini MG, Friso S, Olivieri F, et al. Present and future of anti-ageing epigenetic diets. Mech Ageing Dev pii:S 2014; 0047-6374(13)00136-X.
26. Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009;19(3):706–709.
27. Mastroeni D, Grover A, Delvaux E, et al. Epigenetic changes in Alzheimer’s disease: decrements in DNA methylation. Neurobiol Aging 2010;31(12):2025–2037.
28. Ray D, Wu A, Wilkinson JE, et al. Aging in heterozygous Dnmt1-deficient mice: effects on survival, the DNA methylation genes, and the development of amyloidosis. J Gerontol A Biol Sci Med Sci 2006;61(2):115–124.
29. Levenson JM, Roth TL, Lubin FD, et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 2006;281(23):15763–15773.
30. Rao JS, Keleshian VL, Klein S, Rapoport SI. Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Transl Psychiatry 2012;2:el32.
31. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63(22):7563–7570.
32. Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006;27(2):269–277.
33. Majid S, Dar AA, Shahryari V, et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 2010;116(l):66–76.
34. Fang MZ, Chen D, Sun Y, et al. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2010;11(19 Pt 1):7033–7041.
35. Wang LG, Beklemisheva A, Liu XM, et al. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog. 2007;46(1):24–31.
36. Park LK, Friso S, Choi SW. Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc 2012;71(l):75–83.
37. Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer’s disease. Neurobiol Learn Mem 2011;96(l):19–26.
38. Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010;328(5979):753–756.
39. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2010;35(4):870–880.
40. Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer’s disease mouse model. Neuropsychopharmacology 2009;34(7):1721–1732.
41. Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 2008;106(5):2119–2130.
42. Gräff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012;483(7388):222–226.
43. Kim MJ, Seong AR, Yoo JY, et al. Gallic acid, a histone acetyltransferase inhibitor, suppresses β-amyloid neurotoxicity by inhibiting microglial-mediated neuroinflammation. Mol Nutr Food Res 2011;55(12):1798–1808.
44. Shankar S, Kumar D, Srivastava RK. Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition. Pharmacol Ther 2013;138(1):1–17.
45. Govindarajan N, Agis-Balboa RC, Walter J, et al. Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 2011;26(1):187–197.
46. Dash PK, Orsi SA, Moore AN, et al. Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience 2009;163(1):1–8.
47. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010;142(2):320–332.
48. Longpré F, Garneau P, Christen Y, Ramassamy C. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med 2006;41(12):1781–1794.
49. Yokozawa T, Lee YA, Cho EJ, et al. Anti-aging effects of oligomeric proanthocyanidins isolated from persimmon fruits. Drug Discov Ther 2011;5(3):109–118.
50. Peterson DW, George RC, Scaramozzino F. Cinnamon extract inhibits tau aggregation associated with Alzheimer’s disease in vitro. J Alzheimers Dis 2009;17(3):585–597.
51. Vepsäläinen S, Koivisto H, Pekkarinen E, et al. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer’s disease. J Nutr Biochem 2013;24(l):360–370.
52. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127(6):1109–1122.
53. Karuppagounder SS, Pinto JT, Xu H, et al. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int 2009;54(2):111–118.
54. Porquet D, Casadesús G, Bayod S, et al. Dietary resveratrol prevents Alzheimer’s markers and increases life span in SAMP8. Age (Dordr) 2013;35(5):1851–1865.
55. Davis JM, Murphy EA, Carmichael MD, Davis B. Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am J Physiol Regul Integr Comp Physiol 2009;296(4):R1071–R1077.
56. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425(6954):191–196.
57. Nerurkar PV, Johns LM, Buesa LM, et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation 2011;3;8:64.
58. Rasbach KA, Schnellmann RG. Isoflavones promote mitochondrial biogenesis. J Pharmacol Exp Ther 2008;325(2):536–543.
59. Jayasena T, Poljak A, Smythe G, Braidy N, et al. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer’s disease. Ageing Res Rev 2013;12(4):867–883.
60. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;128(4):669–681.
61. Ambros V. The functions of animal microRNAs. Nature 2004;431(7006):350–355.
62. McKay JA, Mathers JC. Diet induced epigenetic changes and their implications for health. Acta Physiol (Oxf) 2011;202(2):103–118.
63. Somel M, Guo S, Fu N, et al. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res 2010;20(9):1207–1218.
64. Nunez-Iglesias J, Liu CC, Morgan TE, et al. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation. PLoS One 2010;5(2):e8898.
65. Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-l in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 2008;105(17):6415–6420.
66. Liu W, Liu C, Zhu J, et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol Aging 2012;33(3):522–534.
67. Fang M, Wang J, Zhang X, et al. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer’s disease. Toxicol Lett 2012;209(1):94–105.
68. Tan L, Yu JT, Hu N, Tan L. Non-coding RNAs in Alzheimer’s disease. Mol Neurobiol 2013;47(l):382–393.
69. Ross SA, Davis CD. MicroRNA, nutrition, and cancer prevention. Adv Nutr 2011;2(6):472–485.
70. Milenkovic D, Deval C, Gouranton E. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. PLoS One 2012;7(l):e29837.
71. Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med 2013;64:40–51.
72. Tili E, Michaille JJ, Alder H, et al. Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol 2010;80(12):2057–2065.
73. Boesch-Saadatmandi C, Wagner AE, Wolffram S, Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo — role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol Res 2012;65(5):523–530.
74. Parker LP, Taylor DD, Kesterson J, et al. Modulation of microRNA associated with ovarian cancer cells by genistein. Eur J Gynaecol Oncol 2009;30(6):616–621.
75. Zhang J, Du Y, Wu C. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 2010;24(5):1217–1223.
76. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010;21(2):140–146.